Vladimir Tolmachev
Vladimir Tolmachev
Professor of biomedical radiation sciences, Uppsala University
Verified email at
Cited by
Cited by
Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications
J Löfblom, J Feldwisch, V Tolmachev, J Carlsson, S Ståhl, FY Frejd
FEBS letters 584 (12), 2670-2680, 2010
Tumor imaging using a picomolar affinity HER2 binding affibody molecule
A Orlova, M Magnusson, TLJ Eriksson, M Nilsson, B Larsson, ...
Cancer research 66 (8), 4339-4348, 2006
Selection and characterization of HER2/neu-binding affibody ligands
M Wikman, AC Steffen, E Gunneriusson, V Tolmachev, GP Adams, ...
Protein Engineering Design and Selection 17 (5), 455-462, 2004
Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In-or 68Ga-labeled affibody molecules
RP Baum, V Prasad, D Müller, C Schuchardt, A Orlova, A Wennborg, ...
Journal of nuclear medicine 51 (6), 892-897, 2010
Radionuclide Therapy of HER2-Positive Microxenografts Using a 177Lu-Labeled HER2-Specific Affibody Molecule
V Tolmachev, A Orlova, R Pehrson, J Galli, B Baastrup, K Andersson, ...
Cancer research 67 (6), 2773-2782, 2007
First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule
J Sörensen, D Sandberg, M Sandström, A Wennborg, J Feldwisch, ...
Journal of nuclear medicine 55 (5), 730-735, 2014
Measuring HER2-receptor expression in metastatic breast cancer using [68Ga] ABY-025 Affibody PET/CT
J Sörensen, I Velikyan, D Sandberg, A Wennborg, J Feldwisch, ...
Theranostics 6 (2), 262, 2016
Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors
A Orlova, V Tolmachev, R Pehrson, M Lindborg, T Tran, M Sandstrom, ...
Cancer research 67 (5), 2178-2186, 2007
Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain
JT Andersen, R Pehrson, V Tolmachev, MB Daba, L Abrahmsén, ...
Journal of biological chemistry 286 (7), 5234-5241, 2011
Design of an optimized scaffold for affibody molecules
J Feldwisch, V Tolmachev, C Lendel, N Herne, A Sjöberg, B Larsson, ...
Journal of molecular biology 398 (2), 232-247, 2010
Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule
M Friedman, A Orlova, E Johansson, TLJ Eriksson, I Höidén-Guthenberg, ...
Journal of molecular biology 376 (5), 1388-1402, 2008
Pretargeted imaging and therapy
M Altai, R Membreno, B Cook, V Tolmachev, BM Zeglis
Journal of Nuclear Medicine 58 (10), 1553-1559, 2017
Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy
V Tolmachev, A Orlova, FY Nilsson, J Feldwisch, A Wennborg, ...
Expert opinion on biological therapy 7 (4), 555-568, 2007
Preparation and evaluation of 68Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors
I Velikyan, ÅL Sundberg, Ö Lindhe, AU Höglund, O Eriksson, E Werner, ...
Journal of nuclear medicine 46 (11), 1881-1888, 2005
On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model
A Orlova, H Wållberg, S Stone-Elander, V Tolmachev
Journal of Nuclear Medicine 50 (3), 417-425, 2009
Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry
V Tolmachev, M Friedman, M Sandström, TLJ Eriksson, D Rosik, M Hodik, ...
Journal of Nuclear Medicine 50 (2), 274-283, 2009
Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy.
FY Nilsson, V Tolmachev
Current opinion in drug discovery & development 10 (2), 167-175, 2007
Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-ZEGFR:2377 Affibody molecule: aspect of the injected …
V Tolmachev, D Rosik, H Wållberg, A Sjöberg, M Sandström, M Hansson, ...
European journal of nuclear medicine and molecular imaging 37, 613-622, 2010
Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2: 2395, with C-terminally engineered cysteine
S Ahlgren, H Wållberg, TA Tran, C Widström, M Hjertman, L Abrahmsén, ...
Journal of Nuclear Medicine 50 (5), 781-789, 2009
99mTc-maEEE-ZHER2:342, an Affibody Molecule-Based Tracer for the Detection of HER2 Expression in Malignant Tumors
T Tran, T Engfeldt, A Orlova, M Sandström, J Feldwisch, L Abrahmsén, ...
Bioconjugate chemistry 18 (6), 1956-1964, 2007
The system can't perform the operation now. Try again later.
Articles 1–20